135 related articles for article (PubMed ID: 17576063)
1. The discovery of carboline analogs as potent MAPKAP-K2 inhibitors.
Wu JP; Wang J; Abeywardane A; Andersen D; Emmanuel M; Gautschi E; Goldberg DR; Kashem MA; Lukas S; Mao W; Martin L; Morwick T; Moss N; Pargellis C; Patel UR; Patnaude L; Peet GW; Skow D; Snow RJ; Ward Y; Werneburg B; White A
Bioorg Med Chem Lett; 2007 Aug; 17(16):4664-9. PubMed ID: 17576063
[TBL] [Abstract][Full Text] [Related]
2. Structural analysis of carboline derivatives as inhibitors of MAPKAP K2 using 3D QSAR and docking studies.
Nayana RS; Bommisetty SK; Singh K; Bairy SK; Nunna S; Pramod A; Muttineni R
J Chem Inf Model; 2009 Jan; 49(1):53-67. PubMed ID: 19119997
[TBL] [Abstract][Full Text] [Related]
3. Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors.
Rao AU; Xiao D; Huang X; Zhou W; Fossetta J; Lundell D; Tian F; Trivedi P; Aslanian R; Palani A
Bioorg Med Chem Lett; 2012 Jan; 22(2):1068-72. PubMed ID: 22182499
[TBL] [Abstract][Full Text] [Related]
4. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).
Anderson DR; Meyers MJ; Vernier WF; Mahoney MW; Kurumbail RG; Caspers N; Poda GI; Schindler JF; Reitz DB; Mourey RJ
J Med Chem; 2007 May; 50(11):2647-54. PubMed ID: 17480064
[TBL] [Abstract][Full Text] [Related]
5. Pyrazinoindolone inhibitors of MAPKAP-K2.
Goldberg DR; Choi Y; Cogan D; Corson M; DeLeon R; Gao A; Gruenbaum L; Hao MH; Joseph D; Kashem MA; Miller C; Moss N; Netherton MR; Pargellis CP; Pelletier J; Sellati R; Skow D; Torcellini C; Tseng YC; Wang J; Wasti R; Werneburg B; Wu JP; Xiong Z
Bioorg Med Chem Lett; 2008 Feb; 18(3):938-41. PubMed ID: 18221871
[TBL] [Abstract][Full Text] [Related]
6. Novel tetrahydro-beta-carboline-1-carboxylic acids as inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).
Trujillo JI; Meyers MJ; Anderson DR; Hegde S; Mahoney MW; Vernier WF; Buchler IP; Wu KK; Yang S; Hartmann SJ; Reitz DB
Bioorg Med Chem Lett; 2007 Aug; 17(16):4657-63. PubMed ID: 17570666
[TBL] [Abstract][Full Text] [Related]
7. Structural analysis of an MK2-inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800.
Fujino A; Fukushima K; Namiki N; Kosugi T; Takimoto-Kamimura M
Acta Crystallogr D Biol Crystallogr; 2010 Jan; 66(Pt 1):80-7. PubMed ID: 20057052
[TBL] [Abstract][Full Text] [Related]
8. Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) as an antiinflammatory target: discovery and in vivo activity of selective pyrazolo[1,5-a]pyrimidine inhibitors using a focused library and structure-based optimization approach.
Kosugi T; Mitchell DR; Fujino A; Imai M; Kambe M; Kobayashi S; Makino H; Matsueda Y; Oue Y; Komatsu K; Imaizumi K; Sakai Y; Sugiura S; Takenouchi O; Unoki G; Yamakoshi Y; Cunliffe V; Frearson J; Gordon R; Harris CJ; Kalloo-Hosein H; Le J; Patel G; Simpson DJ; Sherborne B; Thomas PS; Suzuki N; Takimoto-Kamimura M; Kataoka K
J Med Chem; 2012 Aug; 55(15):6700-15. PubMed ID: 22746295
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II.
Revesz L; Schlapbach A; Aichholz R; Dawson J; Feifel R; Hawtin S; Littlewood-Evans A; Koch G; Kroemer M; Möbitz H; Scheufler C; Velcicky J; Huppertz C
Bioorg Med Chem Lett; 2010 Aug; 20(15):4719-23. PubMed ID: 20591669
[TBL] [Abstract][Full Text] [Related]
10. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
[TBL] [Abstract][Full Text] [Related]
11. 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.
Harris CM; Ericsson AM; Argiriadi MA; Barberis C; Borhani DW; Burchat A; Calderwood DJ; Cunha GA; Dixon RW; Frank KE; Johnson EF; Kamens J; Kwak S; Li B; Mullen KD; Perron DC; Wang L; Wishart N; Wu X; Zhang X; Zmetra TR; Talanian RV
Bioorg Med Chem Lett; 2010 Jan; 20(1):334-7. PubMed ID: 19926477
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and SAR studies of indole-based MK2 inhibitors.
Xiong Z; Gao DA; Cogan DA; Goldberg DR; Hao MH; Moss N; Pack E; Pargellis C; Skow D; Trieselmann T; Werneburg B; White A
Bioorg Med Chem Lett; 2008 Mar; 18(6):1994-9. PubMed ID: 18291646
[TBL] [Abstract][Full Text] [Related]
13. Structure-based lead identification of ATP-competitive MK2 inhibitors.
Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
[TBL] [Abstract][Full Text] [Related]
14. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4.
Powers JP; Li S; Jaen JC; Liu J; Walker NP; Wang Z; Wesche H
Bioorg Med Chem Lett; 2006 Jun; 16(11):2842-5. PubMed ID: 16563752
[TBL] [Abstract][Full Text] [Related]
15. Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity.
Schlapbach A; Feifel R; Hawtin S; Heng R; Koch G; Moebitz H; Revesz L; Scheufler C; Velcicky J; Waelchli R; Huppertz C
Bioorg Med Chem Lett; 2008 Dec; 18(23):6142-6. PubMed ID: 18945615
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the putative binding conformation of a pyrazolopyridine class of inhibitors of MAPKAPK2 using computational studies.
Miglani R; Cliffe IA; Voleti SR
Eur J Med Chem; 2010 Jan; 45(1):98-105. PubMed ID: 19850376
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.
Cuny GD; Ulyanova NP; Patnaik D; Liu JF; Lin X; Auerbach K; Ray SS; Xian J; Glicksman MA; Stein RL; Higgins JM
Bioorg Med Chem Lett; 2012 Mar; 22(5):2015-9. PubMed ID: 22335895
[TBL] [Abstract][Full Text] [Related]
18. Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors.
Kaptein A; Oubrie A; de Zwart E; Hoogenboom N; de Wit J; van de Kar B; van Hoek M; Vogel G; de Kimpe V; Schultz-Fademrecht C; Borsboom J; van Zeeland M; Versteegh J; Kazemier B; de Roos J; Wijnands F; Dulos J; Jaeger M; Leandro-Garcia P; Barf T
Bioorg Med Chem Lett; 2011 Jun; 21(12):3823-7. PubMed ID: 21565498
[TBL] [Abstract][Full Text] [Related]
19. Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors.
Drung B; Scholz C; Barbosa VA; Nazari A; Sarragiotto MH; Schmidt B
Bioorg Med Chem Lett; 2014 Oct; 24(20):4854-60. PubMed ID: 25240617
[TBL] [Abstract][Full Text] [Related]
20. Multiple and single binding modes of fragment-like kinase inhibitors revealed by molecular modeling, residue type-selective protonation, and nuclear overhauser effects.
Constantine KL; Mueller L; Metzler WJ; McDonnell PA; Todderud G; Goldfarb V; Fan Y; Newitt JA; Kiefer SE; Gao M; Tortolani D; Vaccaro W; Tokarski J
J Med Chem; 2008 Oct; 51(19):6225-9. PubMed ID: 18771253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]